IHI-PROMINENT

How can technology improve dementia care? A European survey of 84 clinicians found data accuracy & ease of use are essential for the clinical adoption of clinical decision support systems. The study was conducted as part of the Innovative Health Initiative (IHI)-funded IHI-PROMINENT project. Read more: https://lnkd.in/e_ytNy3A

We are pleased to announce that the second amendment to the Innovative Health Initiative (IHI) funded IHI-PROMINENT grant agreement has been approved by the European Commission. We would also like to officially welcome our new partners, Nationalt Videnscenter for Demens, Oslo University Hospital, and German Center for Neurodegenerative Diseases (DZNE), to the team!   We look forward to a successful and collaborative journey together. https://lnkd.in/eE5K_WqW

The Innovative Health Initiative (IHI) funded IHI-PROMINENT project supports #Alzheimer’s disease diagnosis amid recommendation of first disease-modifying treatment. Last week, the European Medicines Agency has reaffirmed its positive opinion on lecanemab, following discussions at the February Committee for Medicinal Products for Human Use (CHMP) meeting. On 31 January, Biogen and Eisai announced that the European Commission, as part of its decision-making process, had asked the CHMP to consider new information on the safety of lecanemab, their anti-amyloid immunotherapy for early Alzheimer’s disease. Lecanemab had previously received a positive opinion from the CHMP in November 2024, however the European Commission had asked the CHMP to consider whether this new information might require an update of the opinion. In particular, there were questions around the wording of the risk minimisation measures, and whether the opinion was clear enough to ensure correct implementation of these measures. Following discussions at the February CHMP meeting, the European Medicines Agency announced that no updates would be required to its November opinion. This response has been provided to the European Commission, which will now resume the decision-making process for lecanemab. The recommendation of lecanemab, the first disease-modifying therapy (DMT) for Alzheimer’s disease (AD), by the European Medicines Agency constitutes a major breakthrough for the dementia community. However, several steps still remain before patients can access these new treatments, which are bound to challenge European healthcare systems. A major remaining hurdle is overcoming pricing and reimbursement discussions which will take place within each individual country. Further, health care systems will need to address limited capacity of specialist services for diagnosis and treatment. Supporting clinicians with tools to help them identify the patients most likely to benefit from these new therapies is therefore vital to improve health systems readiness and ensure quality care for people with AD. Read more: https://lnkd.in/g_zuGr7i Hear about the relevance from clinical Geriatrician Hanneke Rhodius-Meester: www.vimeo.com/1029939059 Alzheimer Europe Wiesje van der Flier Juan Domingo Gispert Linus Jönsson Frank Jessen Amsterdam UMC - Amsterdam UMC - Alzheimer Center Amsterdam Combinostics Jean Georges Carlos Díaz Sofie Persson Peter Lindgren Milica G. Kramberger Eino Solje Alina Solomon

🧠 Lovely #ConnAction session yesterday at #ECR2025 in #Vienna. Meike Vernooij invited Harro Seelaar and me to discuss the tremendous progress in the field of #alzheimers, regarding #diagnosis, #prediction and #treatment for an audience of European radiologists. 🤔 What does the advance of blood #biomarkers mean for the role of imaging? How do the possibilities of #PET complement those of #MRI? How can #AI help? What do the novel disease modifying treatments - soon also in the EU - mean for the role of the radiologist? 👉 Multidisciplinary approaches are needed to tackle these challenges. 👉 Bringing innovations from research to clinical practice needs Real World Data and collaboration of all involved. So we can answer the many remaining questions, with the ultimate goal of 👉 Precision medicine, whilst keeping Healthcare accessible and affordable. We discussed all these topics and how we collaborate on them in the Netherlands. Was great fun and we could easily have continued the entire afternoon! Nice to see such progress in the field, and thank you Meike for organizing this amazing session! Amsterdam UMC - Alzheimercentrum Amsterdam Alzheimercentrum Erasmus MC Alzheimer Nederland ZonMw Health~Holland #TAPdementia IHI-PROMINENT #ABOARDproject InRAD – International, practice-based registry for Alzheimer's Disease and other dementias Alzheimer Europe European Society of Radiology

On 31 January, Lena Sannemann and Jyrki Lötjönen from the IHI-PROMINENT project, and Sebastien Libert from Alzheimer Europe held on online consultation with the project’ Public Involvement Board (PIB) to support the development of patient reports for people diagnosed with dementia. Members of the PIB included two relatives of a person with dementia and one carer. The goal of this consultation was to improve the quality, accessibility and ethical aspects of patient reports providing results to patients following clinical tests to assess their cognitive capacities https://lnkd.in/em8hPHv5

📱🧠 Would you like to use a digital test to test your thinking skills? Think, for example, of a memory test on the computer, a language test on the tablet or measuring typing behavior on the smartphone. Researchers Sophie van der Landen and Rosanne van den Berg invited healthy elderly people and patients with early Alzheimer's disease and asked what would motivate or hinder them from using such digital tests. 🔎 What were their findings? In general, older people and patients are positive about digital tests for thinking ability, but they also see challenges. It is important that the tests are in line with personal needs. For example, the participants appreciated personal options such as being able to adjust text size or the ability to take a break. Preferences also differed in how and when the results are shared. Read more about the results of the study here: https://lnkd.in/eUhHNwxE

Welcome to the third Innovative Health Initiative (IHI) IHI-PROMINENT newsletter issue! This and the future newsletter issues will introduce you to our early-career researchers 🌟 and investigators, project achievements 💪as well as our activities. https://lnkd.in/eD-irPWn

The Alzheimer Europe conference #34AEC showcased several initiatives that are shaping the future of Alzheimer’s disease research, with a strong emphasis on collaborative public-private partnerships. These projects, such as PROMINENT, underscore the value of collaborative research, bringing new advances in prevention, diagnosis, and treatment to people affected by, or at risk of dementia. In her opening speech, Elisabetta Vaudano, Principal Scientific Manager at the Innovative Health Initiative (IHI), discussed the transformative impact of these partnerships. Read more: https://lnkd.in/eGWGgRCu

Did you join us at #34AEC in Geneva with our co-hosts Alzheimer Switzerland and Alzheimer Geneva and want to look back at some of the highlights? Did you miss it and want to find out more? Check out our special new publication about the event: https://lnkd.in/e7wADk5R